Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases - Gastroenterology
European Crohn´s and Colitis Organisation - ECCO - Home
Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet's disease from Crohn's disease | Scientific Reports
European Crohn´s and Colitis Organisation - ECCO - OP40 Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohn's Disease patients in the STARDUST trial
Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease - Clinical Gastroenterology and Hepatology
How retail cross-visitation data can inform competitive analysis
European Crohn´s and Colitis Organisation - ECCO - Home
The Loney - By Andrew Michael Hurley (paperback) : Target
IBD treatment plan 'needs to be a continuous conversation'
Sales at ECCO | Water Tower Place
Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy | Bentham Science
Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis - Digestive and Liver Disease
OFF X
European Crohn´s and Colitis Organisation - ECCO - ECCO News
ECCO GOLF AMBASSADOR MINJEE LEE WINS FIRST MAJOR TITLE AT EVIAN CHAMPIONSHIP - The Golf Wire
From single-target to cellular niche targeting in Crohn's disease: intercepting bad communications - eBioMedicine
ECCO Craftsmanship Sustainability Landing Page - ECCO.com
Workflow of the ECCO-GEN EHVol study. Study participants (1) were... | Download Scientific Diagram
European Crohn´s and Colitis Organisation - ECCO - Volume 16, Issue 2
MUC2 and related bacterial factors: Therapeutic targets for ulcerative colitis - eBioMedicine
Frontiers | The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases | Immunology
ECCO Chooses Centric PLM™ for Merchandise-Driven Transformation | Centric Software
:sharpen(level=0):output(format=jpeg)/up/dt/2019/08/shutterstock_768848551.jpg "Alzheimer's drug trial to target P. gingivalis")
Alzheimer's drug trial to target P. gingivalis
New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn's Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab)
